The board of AstraZeneca PLC has rejected the increased US$119 billion takeover offer from US pharmaceuticals firm Pfizer Inc, a decision that has led to a sharp slide in the UK company’s share price as investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.
In a statement yesterday, AstraZeneca’s board said it “reiterates its confidence in AstraZeneca’s ability to deliver on its prospects as an independent, science-led business.”
Pfizer, the world’s No. 2 drugmaker by revenue, has been pursuing No. 8 AstraZeneca since January, saying that their businesses are complementary and would be stronger together. On Sunday, it said it was ready to raise its stock-and-cash offer by 15 percent to US$118.8 billion, or £70.73 billion.
AstraZeneca did not take long to reject the offer, its board saying that Pfizer is making “an opportunistic attempt to acquire a transformed AstraZeneca, without reflecting the value of its exciting pipeline.”
Because Pfizer said it would not raise its offer again or launch a hostile takeover bid over the heads of AstraZeneca’s board, the prospect of a deal looks to be remote, unless AstraZeneca shareholders urge a change of mind. Pfizer has said it hopes AstraZeneca’s shareholders will push for a deal.
Now, AstraZeneca shareholders certainly think a deal is over and the company’s share price slumped 12.9 percent to £41.90.
For weeks, Pfizer has sought the board’s approval for what would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
It would be Pfizer’s fourth deal worth US$60 billion or more since 2000.
Pfizer’s offer comes amid a surge of other deals as drugmakers look to either grow or eliminate peripheral assets to focus on their strengths. Those deals include Switzerland’s Novartis AG agreeing to buy GlaxoSmithKline PLC’s (GSK) cancer-drug business for up to US$16 billion, to sell most of its vaccines business to GSK for US$7.1 billion, plus royalties, and to sell its animal health division to Eli Lilly and Co of Indianapolis for about US$5.4 billion. Canada’s Valeant Pharmaceuticals has made an unsolicited offer of nearly US$46 billion for Botox maker Allergan, which has turned it down, so far.
Pfizer’s latest offer increased from 33 percent to 45 percent the ratio of cash AstraZeneca shareholders would receive. The latest offer would have given them the equivalent of £55 for each AstraZeneca share, split between 1.747 shares of the new company and £0.02476 in cash.
It said the offer represented a 45 percent premium to AstraZeneca’s share price of £37.82 on April 17, before rumors of the deal began circulating.
Pfizer chief executive Ian Read said in a statement that the combination would yield “great benefits to patients and science in the UK and across the globe.”
AstraZeneca has repeatedly rejected Pfizer’s offers, insisting that they significantly undervalue the company and its portfolio of experimental drugs. The company and British government officials also have raised concerns about the prospect of job cuts, facility closures and losing some of the science leadership in the UK, where London-based AstraZeneca is the second-biggest drugmaker, behind GlaxoSmithKline.
Pfizer has made assurances that such cuts would be limited. It has promised to complete AstraZeneca’s research and development hub in Cambridge and to establish the new company’s tax residence, but not headquarters, in England, which would significantly reduce its future tax rate.
However, layoffs are inevitable in big mergers and Pfizer has a track record of eliminating tens of thousands of jobs around the world as a result of its mega deals.
While Pfizer is best known to the public for Viagra, cholesterol fighter Lipitor and other widely used medicines, in the pharmaceutical industry it is known for two other things: marketing muscle and mega mergers, which together have repeatedly propelled it to the top.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”